Saturday, May 18, 2024

How Not To Swelter In Place


 #18,066

Two days ago a derecho with straight-line winds of greater than 100 mph struck metro Houston, Texas leaving 7 dead, and a million people without power.  Today, > 500,000 are reportedly still without power in Harris County, alone, and some may go weeks before power is restored. 

Between tornado outbreaks, derechos, and landfalling hurricanes we see this scenario repeated nearly every year; large regional power outages that can last days, weeks, or sometimes months

Invariably, we see deaths associated with extreme heat or cold, or from carbon monoxide poisoning from using generators, in the days or weeks that follow (see NEJM Mortality in Puerto Rico after Hurricane Maria).

As a Floridian, I've gone through this more than a few times, and even when it isn't life-threatening, going without electricity for days - particularly during the summer - can be miserable.

With Hurricane season starting in a couple of weeks, and the fact that severe weather, earthquakes, and even solar storms can happen at any time, now seems like a good time to review some preparedness options for when the grid goes down. 

Generators are an obvious solution, but they are expensive, loud, emit deadly fumes, and consume fuel at a voracious rate. Keeping enough gas on hand to run more than a day or two is impractical for many, and getting more fuel when the power is off can be nearly impossible. 

Those with tens of thousands of dollars to spend can have a whole-house Solar system - one capable of running freezers, refrigerators, and air conditioners - when the grid goes down.

But on far less of a budget during my last hurricane outage (2022) I had lights, fans, radios, phone and iPad charging capability, and even a mini-DVD player for my entertainment.  

Believe me, under those conditions, having fans was as luxury. 

I detailed my previous solar power system upgrade 3 years ago, in My New (And Improved) Solar Battery Project (for CPAP).

It relied upon a pair of 40 watt solar panels I bought in the early 1990s, and a couple of small (35 amp/hr) lead acid batteries. The panels still work, but are approaching the end of their life, and lead-acid batteries - while cheap - are heavy, have a short (2-4 year life), and can only be discharged about 50% without damage. 

Since they are still serviceable, I haven't replaced them, but a little over a year ago I augmented them with a third (50 amp/hr) LiFePo battery (light, long lasting, and able to discharge > 80%), and a new 100 watt solar panel. 

This new single battery/panel will charge faster, and deliver more power, than the two other batteries combined.  And I did it for roughly $300. 

I'm not going to give a step-by-step tutorial on how to build a system, since there are scores of videos on YouTube that can do that. Instead, I'm going to give an overview of my system, and why I've made the choices I've made. 

If you are at all handy, and comfortable working with 12 volt DC systems, you should be able to cobble together your own system.

Disclaimer: lead acid batteries can offgas Hydrogen, which can be explosive, and should be kept in a ventilated are. A dead short across the terminals of a 12 volt battery can cause a fire or explosion. Reversing the polarity of your connections can fry components. If you are unsure of how to safely deal with batteries or DC voltage, have someone who knows how assist you.

Admittedly, for many people the best solution may be dropping $500-$1000 on a solar generator (really, a battery-inverter), and $150-$400 on a matching solar panel.  Its a plug-and-play solution that can be set up by just about anyone, and they certainly are far more aesthetically pleasing than a home brew setup. 

But if something breaks, you usually have to send it back to the factory for repairs. That turnaround time might be weeks. No matter how good the warranty, it's of limited comfort when the power is already out.  

A home brew system, by its very nature, makes it possible for you to repair it yourself. Except for the cables, a typical system has between 3 and 5 components; Solar panel, Solar Charge Controller, and battery.  For more versatility you can add a 12v/5v USB outlet, and (if desired) a 110v inverter.


For systems of this size, 110v inverters have limited value.  They drain a battery very quickly, and while I have a couple (100 watt & 400 watt), I honestly have a hard time thinking of where I would use them. Charging a laptop, perhaps.

While many of my electrical needs are now met using USB batteries, and small solar panels (see Some Simple Off-The-Shelf Solar Solutions For Power Outages), they won't run my CPAP, larger fans, or a DVD player. 

Still, this may be adequate for a lot of people.  The advantage is, everything is plug and play, relatively inexpensive, will fit into a duffel bag, and you can start small and add components at your own pace.  

As for my new system, it looks like this:

The solar panel is about 18" wide & 39" long.  The battery, LiFePo solar charge controller, and output devices all fit into a plastic crate, and weigh about 12 lbs. It provides dual 12V Car Cigarette Lighter Sockets (for CPAP, or Inverter), 2 USB outlets, and the ability to expand.

Major Parts list: 

  • ECO-WORTHY 12V 50Ah Trolling Motor LiFePO4   $160
  • 100 Watt 12 v Monocrystalline Solar Panel                     $70
  • Solar Charge Controller 10A, Bateria 12V/24V              $18
  • 12V 3A LiFePO4 Battery Charger                                   $20
  • Misc cabling and connectors                                            $20

So, what did my (roughly) $300 upgrade add?

  • With 40-45 amps available from the LiFePo battery I can run my CPAP for 5 (8 hour) nights without recharging.  Or, I can watch 35-40 hours of DVDs, or run a large 12 volt fan for 40+ hours. I can also use it to recharge smaller USB battery banks, run 12 volt lights, radios, etc. 
  • With a 100 watt Solar panel, I can probably average 5+ amps an hour charging, for 4 to 7 hours a day.  On on good day, I could probably recharge the battery from being 80% discharged. 
My two older 35 amp batteries, and solar panels together probably add another 30 to 40 available amp/hrs per day.  All three solar panels, and batteries, weigh in at about 100 lbs, and will fit in the trunk of my car if I have to bug out again. 

I've also invested $10 into a lead-acid trickle wall charger (110 v) and a $20 3 amp LiFePo wall charger (110 v), so I can keep batteries fully charged when the power is on, without having to deploy the solar panels. 

Having this solar gear won't guarantee I'll come away unscathed from the next hurricane, or natural disaster.  But, along with having a propane camp stove and heater, a decent first aid kit, 60 gallons of water stored, a well stocked pantry, and a disaster buddy . . .  it should certainly improve my odds. 


CDC Announces Plans For IRAT Assessment of Texas H5N1 Virus

USDA :  51 Cattle Outbreaks Across 9 States
 

#18,066

A dozen years ago the CDC developed the IRAT (Influenza Risk Assessment Tool) to evaluate the risks of novel flu viruses with zoonotic potential.  In 2012, the list was pretty short:


But 2013-2014 was a major turning point in the evolution of avian (and to a lesser extent, other) flu viruses.  H7N9 appeared in China, along with H5N6, H10N8, H9N2 G1, along with several swine & canine viruses. 

By the end of 2016, the number of viruses on the list had tripled (n=12).

The CDC is quick to point out their Influenza Risk Assessment Tool (IRAT) is not meant to be predictive.  As stated in their FAQ:
Can the IRAT predict a future pandemic?
No. The IRAT is an evaluative tool, not a predictive tool. Flu is unpredictable, as are future pandemics.
But the IRAT can help planners decide which viruses pose the greatest risks, so they can prioritize their efforts and investments.  Today, there are 24 novel influenza A viruses on the IRAT list, with the most recent addition (July 2023) being the 2022 mink-derived H5N1 virus from Spain. 

The IRAT process scores a virus based on 10 parameters (see above).  In this case, the latest IRAT was published roughly 7 months after the outbreak in mink. 

While that assessment increased a number of its risk factors over earlier H5N1 viruses, a few days ago - in Nature Dispatch: Risk Assessment On HPAI H5N1 From Mink - we saw new evidence of limited airborne transmission via ferrets, which may require additional scrutiny. 

Of the 24 novel flu viruses on the CDC's IRAT list, 9 are H5 viruses (4 H5N1, 2 H5N8, 2 H5N6, and 1 H5N2), far and away the most represented HA type.  H7 viruses (H7N9, H7N7, H7N8) come in second, appearing 6 times.  

But in terms of likelihood of emergence, two swine viruses currently top the list: 

Those rankings could change, as last night in A(H5N1) Bird Flu Response Update May 17, 2024, the CDC announced plans to conduct an IRAT assessment on the (A/Texas/37/2024) H5N1 virus, a process that could take several months.  

They wrote:

Beginning the process of conducting a pandemic risk assessment on the virus from the human infection in Texas (A/Texas/37/2024) using the Influenza Risk Assessment Tool (IRAT). The IRAT is an evaluation tool developed by CDC and external flu experts that assesses the potential pandemic risk posed by novel influenza A viruses. The IRAT uses 10 risk elements to measure the potential of an influenza virus to emerge to cause a pandemic as well as the potential public health impact that a pandemic caused by that virus would have.

An IRAT is a multi-step process that can take months to complete. (More on IRAT below.) The current assessment of the risk level to the general public, which is based on available epidemiologic and laboratory data, remains low.

In addition, the CDC listed some of the steps they are taking to deal with the outbreak of H5N1 in dairy cattle, and potential additional spillovers into humans.   I'll have a postscript after the break. 

CDC A(H5N1) Bird Flu Response Update May 17, 2024

          (excerpts) 

May 17, 2024 – CDC continues to respond to the public health challenge posed by a multistate outbreak of avian influenza A(H5N1) virus, or “A(H5N1) virus,” in dairy cows and other animals in the United States. CDC is working in collaboration with the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), state public health and animal health officials, and other partners using a One Health approachUSDA is now reporting that 51 dairy cattle herds in nine U.S. states have confirmed cases of A(H5N1) virus infections in cattle. There have been no additional human cases detected since the one recent case from Texas was reported on April 1, 2024. [1][2

Among other activities previously reported in past spotlights and still ongoing, recent highlights of CDC’s response to this outbreak of influenza A(H5N1) virus in dairy cattle and other animals include:

  • Continuing to support states that are monitoring people with exposure to cows, birds, or other domestic or wild animals infected, or potentially infected, with avian influenza A(H5N1) viruses. To date, more than 300 people have been monitored as a result of their exposure to infected or potentially infected animals, and at least 37 people who have developed flu-like symptoms have been tested as part of this targeted, situation-specific testing. All except the one case in Texas have tested negative. Testing of exposed people who develop symptoms is at the state or local level, and CDC conducts confirmatory testing as needed.
  • Working on a plan for enhanced, nationwide summer monitoring to help ensure that even rare cases of A(H5N1) virus infection in the community would be detected. This plan includes increasing the number of influenza virus specimens that are tested and then subtyped in public health laboratories, which can detect A(H5N1). Nationally, since March 24, 2024, almost 11,000 specimens have been tested for influenza in public health laboratories as part of this surveillance stream. While influenza testing typically declines over the summer, this approach would maintain an increased level of testing. More information on this will be forthcoming.
(Snip)

  • Continuing to monitor flu surveillance data, especially in areas where A(H5N1) viruses have been detected in dairy cattle or other animals, for any unusual trends including in flu-like illness, conjunctivitis, or influenza virus activity.

  • CDC posted influenza A wastewater surveillance data for this first time this week. Wastewater surveillance complements other existing human flu surveillance systems to monitor trends in influenza viruses. Current wastewater monitoring methods detect influenza A viruses but do not distinguish the subtype or source of the influenza A virus (whether it is from humans or animals). Reported levels of influenza A virus from each site are compared against levels reported by the same site during the prior flu season. When influenza A levels in wastewater are high (at the 80th percentile or higher), that triggers follow up by CDC, including outreach to the relevant jurisdiction to determine the source of the signal and intensive surveillance review. The data are presented in the format of an interactive map and updated weekly.
  • Overall, for the most recent week of data, CDC flu surveillance systems show no indicators of unusual flu activity in people, including avian influenza A(H5N1) viruses.

The CDC continues to urge people to be proactive in reducing their risks. 
CDC Recommendations
  • People should avoid close, long, or unprotected exposures to sick or dead animals, including wild birds, poultry, other domesticated birds, and other wild or domesticated animals (including cows).
  • People should also avoid unprotected exposures to animal poop, bedding (litter), unpasteurized (“raw)” milk, or materials that have been touched by, or close to, birds or other animals with suspected or confirmed A(H5N1) virus.
  • CDC has interim recommendations for prevention, monitoring, and public health investigations of A(H5N1) virus infections in people. CDC also has updated recommendations for worker protection and use of personal protective equipment (PPE). Following these recommendations is central to reducing a person’s risk and containing the overall public health risk.
In addition to limiting interactions between infected animals and people, containing the outbreak among animals also is important, which underscores the urgency of the work being done by USDA and animal health and industry partners.


Whether H5N1 will spark a pandemic is anyone's guess - and while it seems unlikely - it could fizzle and recede as it has done in the past.   

Trying to predict what a flu virus will - or won't - do, is a mug's game. 

But another pandemic will come, and our tepid and uncoordinated response to today's threat gives little indication that we'll be ready when that inevitably happens. 

There is still time to correct that.  

But the clock is ticking . . . 


Friday, May 17, 2024

CDC Updated Influenza A in Wastewater Report



Week Ending 5/11/24

#18,065

Earlier this week the CDC unveiled their Influenza A wastewater surveillance program, which receives reports from 674 facilities across the nation, although we've been seeing data from about 1/3rd of those stations over the first 3 weeks. 

This sudden interest in wastewater surveillance has been driven by the recent detection of avian H5N1 in American dairy cattle, and concerns there might be uncaptured spillovers into humans.

These surveillance reports only detect influenza A levels, and do not tell us what subtype, or the likely source.  

But this time of year, we would expect community flu levels to be declining.  

As you can see by the following comparison chart of the past 3 weeks, the number of stations reporting above average rates of influenza have increased week-over-week.  

This despite slightly fewer stations (n=218)  submitting data in this latest report.  








Much of this week's increase is centered in northern California, going from 2 to 5 sites. Again, it isn't clear what might be driving this increase. 

But we will definitely be watching this situation closely over the weeks ahead. 


EID Journal: Antibodies to Influenza A(H5N1) Virus in Hunting Dogs Retrieving Wild Fowl, Washington, USA

#18,064

One of the problems with trying to draw conclusions about the threat posed by HPAI H5 clade 2.3.4.4b is that there are multiple subtypes (H5N1, H5N5, H5N6, etc.) - and scores of genotypes - circulating concurrently around the globe. 

The H5 virus infecting cattle in America is related to - but is genetically distinct from - the H5 viruses infecting sea lions in Chile, farmed mink in Spainraccoons in Nova Scotia, or cats in Poland.

Complicating matters, these viruses continue to evolve slowly via antigenic drift, and generate new genotypes through antigenic shift (reassortment).  HPAI H5 is a continually moving target, meaning past performance does not guarantee future results. 

Most of this viral evolution occurs outside of our view, either in remote regions of the world, or in hosts that are difficult to sample.  Even in more accessible regions, many countries are either ill-equipped - or unwilling - to conduct extensive testing. 

Fortunately, the vast majority of these evolutionary changes will do little to enhance the virus, and many will actually prove a detriment.  Most of these viral GOF experiments will fail to thrive, and wither away into obscurity. 

None of this is to diminish the importance of studies that can only look at a small slice of HPAI H5  conducted over a brief moment in time, but it is important we realize their limitations.  

A seroprevalence study of cattle in the United States six short months ago would have likely reassured us that cattle were not susceptible to H5N1.  Things change. 

With that in mind we have the following study, published this week in the CDC's EID journal that finds low - but significant - number of hunting dogs with antibodies to H5N1 tested over a 2 month period in 2023.  

The authors make it abundantly clear, that this study applies to `subclade 2.3.4.4b H5N1 HPIAV strains that circulated in North America during 2022–2023'.

Due to its length, I've only posted some excerpts (reformatted for better readability).  Follow the link to read it in its entirety.  I'll have a brief postscript after the break. 

Antibodies to Influenza A(H5N1) Virus in Hunting Dogs Retrieving Wild Fowl, Washington, USA

Justin D. Brown , Adam Black, Katherine H. Haman, Diego G. Diel, Vickie E. Ramirez, Rachel S. Ziejka, Hannah T. Fenelon, Peter M. Rabinowitz, Lila Stevens, Rebecca Poulson, and David E. Stallknecht

Abstract

We detected antibodies to H5 and N1 subtype influenza A viruses in 4/194 (2%) dogs from Washington, USA, that hunted or engaged in hunt tests and training with wild birds. Historical data provided by dog owners showed seropositive dogs had high levels of exposure to waterfowl.
(SNIP)

Despite the prolonged global epizootic of HPIAV H5N1, reported infections in dogs have been rare.

    • During an HPIAV H5N1 outbreak in Thailand, a fatal canine infection in 2004 associated with a dog eating a duck carcass was reported (1).
    •  A follow-up serosurvey of outwardly healthy stray dogs in Thailand detected HPIAV H5N1 antibodies in 25.4% (160/629) of sampled dogs (2).
    •  During April 2023, another fatal HPIAV H5N1 infection was identified in Ontario, Canada, in a dog that developed severe respiratory and systemic signs shortly after chewing on a dead wild goose (3).
    •  In experiments, beagles were susceptible to HPIAV H5N1 infections, during which some infected dogs excreted high concentrations of virus through the respiratory tract and experienced severe disease (4).
    •  In contrast, previous studies in beagles reported susceptibility to HPIAV H5N1 infection that manifested with moderate to no clinical signs (5,6).

Existing field and experimental data collectively suggest dogs are susceptible to HPIAV H5N1 infection but clinical outcomes vary. However, infection appears to be restricted to dogs with high virus exposure. To investigate this further, we tested for antibodies to influenza A(H5N1) virus in bird hunting dogs, a category of dogs at high risk for contact with HPIAV H5N1–infected wild birds, and compared serologic results to reported hunting or training activities.
Dog owners completed a questionnaire providing details about their dogs’ retrieving activities, canine influenza virus (CIV) vaccination status, and clinical history. Methods used in this research were approved by the Institutional Animal Care and Use Committee at Penn State University (#202302394).

During March–June 2023 in Washington, USA, we collected blood samples from 194 dogs identified by owners as having engaged in bird hunting or bird hunt tests and training over the previous 12 months (Figure). Waterfowl hunting season in Washington extends from mid-October through February; consequently, we collected samples 1–4 months after season closure. We collected blood from the jugular vein, immediately centrifuged it, and stored it at 4ºC in the field, then stored serum at –20°C until testing was performed.

(SNIP)

We used conservative positive threshold titers: H5 HI, >1:32; H5 VN, >1:20; and N1 ELLA, >1:80. We considered samples H5 seropositive if positive for H5 using HI assay or VN and N1 seropositive if positive for N1 using ELLA. We also tested all bELISA-positive serum samples for antibodies to H3N2 and H3N8 CIV by HI assay (positive threshold ≥1:8) (9). We calculated seroprevalence using R (10).

Most dogs retrieved waterfowl (86%), and many (69%) retrieved both waterfowl and upland game birds (Appendix Tables 1, 2). Dogs most commonly contacted dabbling ducks (81% of dogs), which are notable reservoirs for HPIAV H5N1. Dogs also frequently contacted birds from other categories considered high risk for HPIAV H5N1, including geese (32% of dogs) and diving ducks (23% of dogs) (Appendix Table 3). Most dogs had retrieved or trained multiple times during the previous 12 months; 38% were reported to have been in the field during ≥15 hunts and 78% reported to have trained with live or dead birds ≥15 times (Appendix Table 2). Reportedly 11% of dogs retrieved dead or clinically ill waterfowl that showed no evidence of having been shot or hunted.

(SNIP)

Over the previous 12 months, all 4 H5- and N1-seropositive dogs reportedly had hunted waterfowl extensively in areas affected by H5N1 HPIAV outbreaks in wild waterfowl. Three H5- and N1-seropositive dogs reportedly had retrieved waterfowl that were either dead or had neurologic symptoms but that showed no evidence of having been shot or hunted.
Two H5- and N1-seropositive dogs were from households that owned multiple hunting dogs included in this study; 1 seropositive dog was 1 of 2 dogs included in the study and the other was 1 of 3. None of the other tested dogs from those multidog households were seropositive for IAV. 

Conclusions

We detected antibodies to H5 and N1 only in hunting dogs with high levels of bird hunting and waterfowl retrieval. Although that finding suggests transmission of HPIAV H5N1 from waterfowl to dogs can occur, low seroprevalence, lack of reported disease in seropositive dogs, and lack of evidence for dog-to-dog transmission among dogs sharing households collectively indicate that the subclade 2.3.4.4b H5N1 HPIAV strains that circulated in North America during 2022–2023 were poorly adapted to dogs.
Those results suggest that effective risk communication with hunting dog owners could be an inexpensive and effective strategy to reduce the potential for spillover to dogs, and monitoring hunting dogs for IAV could be a useful addition to existing surveillance efforts.

Dr. Brown is an assistant teaching professor in the Department of Veterinary and Biomedical Sciences in the College of Agricultural Sciences at Pennsylvania State University. His research focuses on defining the impacts of infectious diseases on wildlife populations.


Last month, in Microorganisms: Case Report On Symptomatic H5N1 Infection In A Dog - Poland, 2023, we looked at a much different case report, with the authors writing:

The case described in our report confirms that on rare occasions the A/H5N1 virus can also induce a natural severe respiratory disease in dogs. While in some of them the infection remains asymptomatic, capable of shedding the virus [35], others exhibit mild symptoms such as transient fever [34], or even fatal disease [20].

 The authors also note:

In Poland, as in most European countries, dogs presenting with respiratory symptoms are not routinely tested for influenza.

Different country, different time, different genotype . . .  different outcome. 

While this is likely an outlier, the more I write about novel flu viruses, the less inclined I am to make blanket assumptions about what a given strain can - or can't - do. 

Thursday, May 16, 2024

Nature Dispatch: Risk Assessment On HPAI H5N1 From Mink



Credit ECDC

#18,063

Although we constantly hear that HPAI H5N1 still needs to acquire a number of specific genetic mutations before it could pose a human pandemic threat, no one really knows what those changes might be.   

We do have a short list of known or suspected mammalian adaptations - amino acid changes that occur at specific locations in the genome - that are believed to enhance its ability to infect, replicate, or transmit among mammals. 

But we certainly don't know all of them, or how they may `play together' in different combinations.  

A dozen years ago, Virologist Ron Fochier controversially demonstratedthat an older clade of H5N1 could be made to transmit via the airborne route (see CIDRAP Fouchier study reveals changes enabling airborne spread of H5N1).

Our current clade (2.3.4.4b) is quite different from that older virus, and while we've seen a huge increase in mammalian infections - and mammal-to-mammal transmission - evidence of airborne spread remains scant. 

Alarms were raised, however, in the fall of 2022 when H5N1 began spreading rapidly through a large mink farm in Spain (see Eurosurveillance: HPAI A(H5N1) Virus Infection in Farmed Minks, Spain, October 2022). 

Mink are a member of the Mustelidae family of carnivorous mammals, which also includes otters, badgers, weasel, martens, ferrets, and wolverines. Many of these species are susceptible to flu viruses – most notably ferrets – which are often used in influenza research.  

Spillovers into farmed animals are particularly worrisome, because they allow for serial transmission across a large number of hosts, which may result in host adaptation (a technique used by Fouchier in creating his transmissible H5N1). 

    

This mink-derived H5N1 virus from Spain carried a rare mutation (PB-T271A), which is believed to `enhance the polymerase activity of influenza A viruses in mammalian host cells and mice', and which has subsequently been reported in outbreaks in fur farms in Finland.

Last summer, the CDC issued an IRAT Risk Assessment On Mink Variant of Avian H5N1finding it's scores had risen in 6 of the 10 parameters used to evaluate their zoonotic potential (see chart below).


Despite an encouraging report a week ago (see Emerg. Inf. & Microbes: Pigs are Highly Susceptible To But Do Not Transmit Mink-Derived HPAI H5N1 Clade 2.3.4.4b), today we have a far more concerning dispatch - published in Nature - that finds ferrets are able to transmit a recombinant version of this mink H5N1 virus efficiently (75%) via direct contact and far less efficiently (37.5%) via the airborne route. 

Curiously, transmission in both cases was delayed by several days, although there was no indication of in-host mutations causing this. 

This is a lengthy, highly detailed, report with a lot to unpack. I've posted some excerpts below, but is really should be read in its entirety. I'll return after the break with more. 

Risk assessment of a highly pathogenic H5N1 influenza virus from mink

Katherine H. RestoriKayla M. SepterCassandra J. FieldDevanshi R. PatelDavid VanInsbergheVedhika RaghunathanAnice C. LowenTroy C. Sutton

Nature Communications volume 15, Article number: 4112 (2024)  

Abstract

Outbreaks of highly pathogenic H5N1 clade 2.3.4.4b viruses in farmed mink and seals combined with isolated human infections suggest these viruses pose a pandemic threat. To assess this threat, using the ferret model, we show an H5N1 isolate derived from mink transmits by direct contact to 75% of exposed ferrets and, in airborne transmission studies, the virus transmits to 37.5% of contacts.

Sequence analyses show no mutations were associated with transmission. 

The H5N1 virus also has a low infectious dose and remains virulent at low doses. This isolate carries the adaptive mutation, PB2 T271A, and reversing this mutation reduces mortality and airborne transmission. 

This is the first report of a H5N1 clade 2.3.4.4b virus exhibiting direct contact and airborne transmissibility in ferrets. These data indicate heightened pandemic potential of the panzootic H5N1 viruses and emphasize the need for continued efforts to control outbreaks and monitor viral evolution.

          (SNIP)

To cause a pandemic, an influenza A virus must be able to replicate efficiently in humans and transmit via the airborne route from person-to-person. Owing to similarities to humans in their susceptibility, ferrets are a valuable model in which to evaluate influenza virus transmission and pathogenesis, and ferrets are routinely used to assess pandemic risk.

Ferrets possess a similar distribution of viral receptors (i.e.,α 2,6-linked sialic acids) to that observed in humans and, upon infection with human influenza viruses, ferrets develop clinical illness and shed high levels of infectious virus. Also consistent with influenza in humans, ferrets infected with human-adapted strains transmit the virus through the air to contact animals8.

To date, no subclade 2.3.4.4b highly pathogenic H5N1 virus has exhibited the ability to transmit by the airborne route, a feature thought to be critical in limiting their outbreak potential in humans. However, experimental studies have demonstrated the potential for an ancestral clade 2.1.3.2 H5N1 virus to become airborne transmissible in ferrets9.

(SNIP)

To assess the risk to humans, we evaluated the potential for an H5N1 isolate from this mink outbreak to infect, cause disease, and transmit in ferrets. As isolates from the mink outbreak could not be readily obtained, we generated recombinant influenza A/mink/Spain/3691-8_22VIR10586-10/2022 (H5N1) virus [A/mink (H5N1)] using reverse genetics.

(SNIP)

All viruses from this outbreak carried the mammalian-adaptive mutation T271A, and several additional mutations were identified throughout the genome; however, as previously reported, the function of these later mutations is unknown10.

Virus rescue or regeneration, and all subsequent experiments were performed following strict biosafety protocols in our biosafety level 3 enhanced facility, and all studies were conducted following all local, state, and federal rules and regulations.

(SNIP)

Discussion

Collectively, our studies show that the A/mink (H5N1) virus transmitted efficiently by direct contact, with 75% of contact animals infected, and inefficiently via the airborne route with 37.5% of respiratory contact animals developing an infection.

Sequence analyses of viruses shed in the nasal wash from infected donor and contact animals did not show evidence of positive selection acting during direct contact or airborne transmission. In dose de-escalation studies, the A/mink (H5N1) virus had a low infectious dose, and the virus was highly virulent across a wide range of doses as all infected animals developed severe disease.

Although we observed efficient direct contact transmission, it was delayed relative to that seen previously with pandemic influenza viruses. For pandemic influenza viruses, viral shedding in direct contacts often begins on day 1 p.c. 14,15. Here, the onset of shedding was on day 3 p.c. in one contact, and on days 7 and 9 p.c., respectively, in the others. While airborne transmission was observed, it occurred at lower efficiency than is typical for pandemic influenza viruses.

         (SNIP) 

The low median infectious dose observed for A/mink (H5N1) was comparable to the two most recent pandemic influenza viruses, indicating that the ability to infect and replicate in ferrets is not likely limiting transmission. Prior adaptation studies have shown that changes in the HA to reduce the pH of fusion and enhance binding to α2-6-linked sialic acids combined with mutations to enhance polymerase activity in mammalian cells are required for airborne transmission of a highly pathogenic clade 2.3.1.2 H5N1 virus 9,32.

The A/mink (H5N1) virus does not carry mutations known to reduce the pH of fusion or enhance binding to α2-6-linked sialic acids; however, the virus does carry the PB2 T271A mutation which has been shown to enhance polymerase activity and replication of avian viruses in mammalian cells. Consistent with this observation, we show that reversing the PB2 mutation (i.e., 271T) in A/mink (H5N1) reduced viral polymerase activity in mini-genome assays.

Moreover, introducing the PB2 A271T mutation reduced mortality and resulted in a reduction in the number of RC ferrets that shed virus in airborne transmission studies. This was associated with reductions in viral titers in the nasal wash which were not significant at lower inoculation doses used to assess virulence but were significant at high inoculation doses used for transmission studies. These findings indicate the PB2 T271A mutation is enhancing viral replication of the A/mink (H5N1) virus contributing to both virulence and transmission in ferrets.

As our studies assessed viral load in the nasal wash, future studies are warranted to assess the impact of the PB2 T271A mutation on viral replication in the lungs and systemic dissemination of the virus. Moreover, evaluating the role of the PB2 T271A mutation in the context of direct contact transmission will yield additional insight on the contribution of this mutation to the overall transmissibility of the virus.

An important consideration in interpreting our results with respect to the risk posed to humans is that the ferrets used in these studies have no pre-existing immunity to influenza, whereas the majority of humans have been exposed to H1N1 and H3N2 seasonal influenza viruses. While different influenza A virus subtypes are antigenically distinct, some degree of cross-protection against H5N1 may be conferred by prior exposure to these seasonal strains, especially against the N1 neuraminidase. Indeed, antibodies and T cells against seasonal influenza viruses have been shown to cross-react with H5N1 viruses33,34,35,36,37,38.

Future studies are warranted to determine if prior immunity reduces disease severity and/or transmission.

In conclusion, this is the first report of both direct contact and limited airborne transmission in a mammalian model of a subclade 2.3.4.4b H5N1 virus indicating these viruses pose a significant pandemic threat. Therefore, ongoing risk assessment and enhanced surveillance in wild and domestic animals is warranted to monitor the threat posed by these viruses as they continue to evolve and spillover into mammals, including humans.

          (Continue . . . )


While the headline may be that ferrets were found able to transmit this virus via both contact and airborne routes, the bigger news for me is that it was able to do so without first acquiring any of the `usual suspects' from the mammalian adaptation list. 

The A/mink (H5N1) virus does not carry mutations known to reduce the pH of fusion or enhance binding to α2-6-linked sialic acids; however, the virus does carry the PB2 T271A mutation

Furthermore, by changing out that PB2 T271A mutation to PB2 A271T, the virus immediately became less effective. The authors stating:

These findings indicate the PB2 T271A mutation is enhancing viral replication of the A/mink (H5N1) virus contributing to both virulence and transmission in ferrets.

While T271A alone may not be enough to make H5N1 a pandemic contender, it is doing an impressive amount of heavy lifting.  And, of course, if T271A can do this, there may be other evolutionary shortcuts we aren't aware of. 

This dispatch also touches on potential (albeit, likely limited) pre-existing immunity to H5N1. 

This is something we've looked at before, in EID Journal: A(H5N1) NA Inhibition Antibodies in Healthy Adults after Exposure to Influenza A(H1N1)pdm09 and in Frontiers Vet. Sci: Influenza Virus Immune Imprinting - Clinical Outcome In Ferrets Challenged with HPAI H5N1.

Whether it is occurring birds, in farmed mink, in dairy cattle, in peridomestic mammals, or in humans, H5N1 is engaged in a relentless series of GOF (Gain of Function) experiments.  

With each passing day new hosts are infected, new genotypes are produced, and random amino acid changes are introduced.  While the virus still lacks the `spark' to ignite a pandemic, it appears to be a lot closer today than at any time we've seen it in the past. 

And if we get very lucky - and H5N1 doesn't have the `right stuff' - we can be pretty certain there are other novel flu viruses that do.  

It's just a matter of time.  

Wednesday, May 15, 2024

CDC Update: New Influenza A Dashboard & Reporting Changes For Hospitals


 #18,062

In a case of exceptionally bad timing, 2 weeks after the first cattle-related H5N1 human infection was reported (April 1st) in Texas, the following notice appeared in the CDC's weekly Fluview Report announcing the latest in a series of rollbacks of reporting requirements on COVID, Flu, and other respiratory illnesses.  

This decision was made long before the discovery of H5N1 in cattle, and is part of an ongoing, albeit short-sighted global move to dismantle COVID surveillance and reporting, something we've discussed ad nauseam for more than 2 years (see here, here, here, here, and here). 

While proponents may argue this is good for the world's economies who need to `move on' from the pandemic, and others may find it politically expedient, it has left the world at a distinct disadvantage when it comes to collecting and analyzing data on new and emerging COVID variants and other emerging disease threats.

Late yesterday the CDC published an update (see below - emphasis mine) which acknowledges the impact of recent changes to reporting - and encourages hospitals to continue to report as they did before this change took effect - while they work to rectify the situation. 

CDC Updates Respiratory Virus Dashboards

May 14, 2024, 6:00 PM EDT
Updates on respiratory illness and vaccine-preventable diseases.

CDC Updates Hospitalization Data on Respiratory Virus Dashboards

CDC keeps a close eye on respiratory viruses and the diseases they cause through a range of systems that collect data on hospitalizations, deaths, emergency department visits, wastewater findings, and testing results. But as of April 30, 2024, some federal reporting requirements for acute care hospitals and critical access hospitals expired. While CDC has access to other robust and reliable surveillance systems to track hospitalization trends for COVID-19, flu, and RSV, CDC is updating its respiratory virus dashboards to reflect this change.
What’s changing with hospital reporting requirements?

On April 30, 2024, some Centers for Medicare & Medicaid Services (CMS) federal reporting requirements for acute care hospitals and critical access hospitals expired. For now,
hospitals are no longer required to report certain COVID-19, flu, and other acute respiratory illness-related hospitalization and bed capacity data to CDC’s National Healthcare Safety Network (NHSN).

Despite this change in mandatory reporting, CDC and CMS are encouraging hospitals to continue submitting data voluntarily to NHSN. CDC has begun sharing the voluntarily reported data on its website with weekly updates. Full details on NHSN hospital data reporting guidance are available on the NHSN website.
These data have proved invaluable for informing public health decisions, including during the COVID-19 Public Health Emergency and throughout the 2023/24 respiratory virus season. CDC, CMS, and the Administration for Strategic Preparedness and Response worked together on new proposed requirements for hospitals to electronically report information about COVID-19, flu, RSV, and hospital bed capacity in a standardized format and frequency specified by the HHS Secretary. This proposed requirement aims to strike a balance between the need for critical data to inform hospital decision-making while not making these data overly burdensome to report. If finalized, this proposed new standard would take effect October 1, 2024.
This proposed rule is open for public comment until June 10, 2024, and CDC encourages interested public health and healthcare partners to respond.

CDC continues to monitor and share hospitalization data

Key COVID-19, flu, and RSV information currently available on CDC’s COVID Data Tracker and Respiratory Virus Data Channel will remain available, thanks to data collected through other CDC surveillance systems, including COVID-NET, FluSurv-NET, and RSV-NET that constitute RESP-NET.

COVID-NET, FluSurv-NET, and RSV-NET provide data that help CDC continue to track and monitor COVID-19-, flu-, and RSV-associated hospitalization trends, respectively, and determine who is most at risk. COVID-NET collects data on laboratory-confirmed COVID-19-associated hospitalizations among children and adults from over 300 acute care hospitals in 13 states, representing about 10% of the US population. FluSurv-NET and RSV-NET have comparable structures and characteristics. The population covered in the communities within these systems have similar demographics as the overall U.S. population, making them good tools for understanding national COVID-19 and flu hospitalization trends, even without nationwide data. All three systems provide detailed, patient-level information about respiratory virus-associated hospitalizations (for example, demographics, underlying conditions, clinical outcomes).

CDC also operates the National Syndromic Surveillance Program (NSSP), a collaboration among CDC, local and state health departments that collects, shares, and analyzes these automated electronic healthcare data, including patients presenting to the Nation’s emergency departments who are diagnosed with COVID-19 and other conditions. These data provide public health officials with a timely system for detecting, understanding, and monitoring health events. By tracking symptoms and diagnoses of patients in emergency departments in near real-time, public health can detect unusual levels of illness or injury to determine whether a response is warranted.
What changes are occurring to CDC dashboards?
  • COVID Data Tracker is CDC’s flagship website for comprehensive data on COVID-19. Current hospital data visualizations using NHSN data, including those used to calculate COVID-19 County Hospital Admission Levels, have been archived. These have been replaced with visualizations that display data that hospitals voluntarily submit to CDC’s NHSN. This includes inpatient and intensive care unit bed occupancy and reporting completeness summaries. While we continue to assess the quality and completeness of NHSN hospitalization data on respiratory viruses during the voluntary reporting period, we are changing the main COVID-19 hospitalization dashboard from using NHSN data to COVID-NET findings.
  • The Respiratory Virus Data Channel is CDC’s one-stop shop for main data findings concerning the “big 3” viral respiratory illnesses—COVID-19, flu, and RSV. Current hospital data visualizations for COVID-19 and flu hospitalizations using NHSN data have been archived from this site and replaced with the respective findings from COVID-NET and FluSurv-NET; RSV-NET findings will continue to be displayed on the site.
  • Data.cdc.gov is CDC’s central web-based platform that provides access to data published by CDC for partners and the public. Datasets that include the historical NHSN data have been archived and remain available on data.cdc.gov for public use. In addition, voluntarily reported NHSN hospital data products that include information on COVID-19 and flu will be made available to provide transparency in continued data collection efforts; these datasets can also be found on healthdata.gov.
While NHSN continues to be available for reporting among all U.S. hospitals, the change in reporting requirements may impact completeness of the data submitted and information may fluctuate from week to week. CDC will continue to assess the quality and completeness of voluntarily reported NHSN hospital data to understand which are most informative for patient safety and public health actions. 

Looking ahead: Leaning on multiple systems and new reporting requirements

CDC will continue to collect and disseminate data from other sources—such as wastewater, laboratories, and emergency departments—to detect and monitor threats and keep its partners and the public informed about threats in their communities.

CDC will also continue to work with hospitals, health systems, and state, tribal, local, and territorial agencies to streamline reporting requirements and further minimize burden on healthcare systems. CDC has already invested more than $1 billion to increase the automation capabilities of surveillance systems such as NHSN and NSSP and its ability to connect with other data submission techniques, vendors, and systems.

Over time, reporting capabilities will become increasingly automated, standards-based, simplified, and real-time as data systems mature and become more interoperable. Thanks to hard work in collaboration with partners across the country, we will still be able to collect data that are valuable to situational awareness and public health decision-making. As the disease dynamics and impacts of respiratory viruses including COVID-19 continue to change, it is critical that we continue investing in systems that will allow us to track critical changes and take action that can save lives.

As we've discussed previously, each year we see an average of 2 or 3 new zoonotic diseases emerge around the world (see chart below), and several recent journal articles (see here and here) suggesting  that rate will continue to escalate in the coming years. 



It shouldn't take a Nostradamus to know that this is precisely the wrong time to be reducing our global surveillance and reporting systems. But that is exactly what has happened over the past few years, and it extends far beyond just COVID.  

A little over a year ago, in Lancet Preprint: National Surveillance for Novel Diseases - A Systematic Analysis of 195 Countries, we saw a report indicating the self-reported compliance to the IHR (adopted in 2007) has been routinely overstated by many countries for more than a decade.  

And 18 months ago, in Flying Blind In The Viral Storm, we looked at the increasing willingness of many countries to delay, downplayor hide completely reports of emerging infectious disease events. 

A classic example being China's under-reporting (by millions) of the number of COVID deaths in early 2023.  

As a result, our `global awareness' of emerging disease threats is probably lower today than it was before the start of the COVID pandemic. While we may not always like what we find, one of the lessons from COVID should have been:

More knowledge, sooner, can save lives. 

Unfortunately, that's a lesson we apparently have yet to fully embrace.